Our PLA Navigator is an automated solution for complex PLAs and OBAs, to track compliance and avoid unnecessary risk with enhanced reporting and auditing accuracy, leveraging the vast data sources available through our integrated services.

A well-developed submission is key to securing a positive listing recommendation and ensuring timely patient access. We help manufacturers demonstrate clinical and economic value to payers by communicating the value proposition of new products within the framework of the payer reimbursement review processes. In alignment with our clients, we develop messaging in submissions that clearly conveys the unique product characteristics that are important in the Canadian market access environment. Whether we manage the complete submission process, or tailor our support to incorporate administrative components for what you’ve already developed, we help ensure that you’re well-positioned for a successful product listing in Canada with both public and private payers.

We understand the importance that real-world evidence plays in market access success. Demonstrating the clinical and economic benefit of your product is vital to obtaining reimbursement. Our experienced team of health economists can help you with health economic modeling for submissions; publication and study development, including Observational, Willingness-to-Pay, Pay for Performance models and Burden of Illness studies; and Canadian adaptation of global economic models.

We have extensive experience building budget impact analyses (BIAs) for complex specialty products, including rare disease, oncology and immunology (including biosimilar) products; as well as medical device and diagnostics. Our BIA models are developed within established guidelines of individual public and private payers, and clearly articulate the incremental impact to the drug plan’s bottom-line.